Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;45(5):926-34.
doi: 10.1016/j.humpath.2014.01.005. Epub 2014 Jan 25.

The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer

Ming-Hui Ao  1 , Hui Zhang  1 , Lynne Sakowski  1 , Rajni Sharma  1 , Peter B Illei  1 , Edward Gabrielson  1 , Frederic Askin  1 , Qing Kay Li  2
Affiliations

The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer

Ming-Hui Ao et al. Hum Pathol. 2014 May.

Abstract

In lung cancer, targeted therapies depend on accurate histological subclassification of the tumor. The majority of lung cancers can be subclassified based on hematoxylin and eosin staining; however, classification may be difficult in small biopsies. In this study, we investigated the utility of a newly developed triple marker (combination of TTF1/Napsin A/p40) and compared the sensitivity and specificity of this novel marker with individual markers in the subclassification of non-small cell lung carcinomas. Lung cancer tissue microarrays were constructed using surgical resection material from the Johns Hopkins Hospital. They included 77 adenocarcinomas (ADCs), 77 squamous cell carcinomas (SqCCs), and 46 cases of metastatic lung ADCs. Immunostaining patterns of all markers were scored semi-quantitatively and compared. In ADCs, the sensitivity and specificity of the triple marker were 93.5% and 77.5%, respectively. The sensitivity and specificity of TTF1 and Napsin A were 85.7% and 75.0%, and 89.6% and 90.0%. In SqCCs, the sensitivity and specificity of the triple marker were 88.3% and 92.5%, while the p40, p63 and CK5/6 showed 80.5% and 90.0%; 93.5% and 80.0%; and 89.6% and 80.0%. In addition, the sensitivity and specificity of the triple marker in metastatic ADCs showed 71.7% and 73.5%, respectively. Our triple marker (combination of TTF1/Napsin A/p40) showed a similar sensitivity and specificity for the subclassification of NSCLC when compared to individual markers. Our study not only demonstrates a useful combination of immunomarkers but also optimally conserves tissue for molecular marker testing.

Keywords: Immunohistochemical markers; Napsin A; Non–small cell lung carcinoma (NSCLC); Novel triple stain marker; P40.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Staining pattern of the triple marker in TMA of primary ADCs. The TMA was scanned using Aperio’s ImageScope. The photo of entire TMA was taken at original magnification (1×), and photos of individual scores were taken at 4× magnification.
Fig. 2
Fig. 2
Comparison of triple marker stains with TTF1 and Napsin A in TMA of primary ADCs. A, Immunoscores of TTF1 and Napsin A in TMA of primary ADC (4×, Aperio’s ImageScope). B, The heat map and bar graph of IHC stains.
Fig. 3
Fig. 3
Staining pattern of the triple marker in TMA of primary SqCCs. The TMA was scanned using Aperio’s ImageScope. The photo of entire TMA was taken at original magnification (1×), and photos of individual scores were taken at 4× magnification.
Fig. 4
Fig. 4
Comparison of triple marker stains with p63, p40 and CK5/6 in TMA of primary SqCCs. A, Immunoscores of p63, p40 and CK5/6 in TMA of primary SqCCs (4×, Aperio’s ImageScope). B, The heat map and bar graph of IHC stains.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. - PubMed
    1. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85. - PMC - PubMed
    1. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3:1468–81. - PubMed
    1. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011;6:1601–12. Review. - PubMed
    1. Munfus-McCray D, Cui M, Zhang Z, Askin F, Gabrielson E, Li QK. Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect. HUM PATHOL. 2011;42:1447–53. - PubMed

Publication types

MeSH terms